New Name. Same A2M Concentration Commitment.

APIC-A2M is now ALPHA2ACTIVE™! We’ve redesigned our patented, 510(k) approved Alpha-2-Macroglobulin (A2M) therapy to reflect the worldwide expansion to come and give you an edge as you reopen in today’s medical climate. Read the official press release here. ALPHA2ACTIVE™ may have a fresh new look, but the single-use kits include the same easy processing steps, high A2M concentration and protease binding benefits as before.

ALPHA2ACTIVE™ is an exciting advancement in orthopedic science resulting from years of osteoarthritis research. For the majority of people with pain, their arthritic joint or disc space houses more destructive enzymes than the body can handle. Alpha-2-Macroglobulin, more commonly referred to as A2M, is a master protease inhibitor that already exists in your blood and acts as a powerful inhibitor of cartilage breakdown.

It is our body’s own defense mechanism.  This special molecule works by binding to the enzymes (proteases) that degrade the cartilage cells and tissue. However, it is too big and complex to enter the joint or disc space in large enough quantities. As a result, it is necessary to inject additional concentrated A2M into the affected area to restore balance and relieve pain.

A patented and proprietary filtration process has been developed that can concentrate the naturally occurring A2M molecule from a patient’s own blood up to 6X! This process allows therapeutic injections in concentrated dosages that:

  • Boost natural healing by reducing the additional deterioration of cartilage and inflammation
  • First and only system to centrifuge and filter plasma
  • Settings for both PRP and PPP processing
  • Low percentage of white blood cells eliminating unnecessary pain from the treatment
  • Support tissue growth with naturally occurring compounds from your own blood

Instagram

Know for a F.A.C.T.

The Fibronectin-Aggrecan Complex Test (FACT™) is a molecular biomarker test used to identify symptomatic intervertebral discs or painful joint abnormalities. FACT™ is used to measure the presence of the Fibronectin-Aggrecan Complex (FAC) in a fluid specimen taken from patients with musculoskeletal pain. FAC is a unique molecular complex that is specific for painful inflammation of the spine and joints. FACT™ is used to identify symptomatic intervertebral discs and joints by the process of Molecular Discography™ and Systematic Joint Diagnostics respectively.

Benefits of Using FACT™
There are two types of kits available. The Joint Diagnostic Collection kit which is primarily utilized in large joints. The Molecular Discography Collection kit which is utilized to collect specimens from the spine.

  • Predicts a positive functional outcome. Clinical tests show more
    than 90% of FAC positive patients have significant improvement.
  • Provides an objective measurement to support the treatment
    algorithm for the patient: Physicians pull a synovial or lavaged
    fluid sample during an initial consult or scheduled procedure to
    confirm the diagnosis and outline next steps.
  • Results are typically shared within a week or two.

Learn More About FACT™

Menu
X